PMID: 9549639Apr 29, 1998Paper

Chelation therapy in cardiovascular disease: ethylenediaminetetraacetic acid, deferoxamine, and dexrazoxane

Journal of Clinical Pharmacology
N ElihuW H Frishman

Abstract

This review was conducted to assess whether there is sufficient evidence for the clinical use of chelation therapy in cardiovascular disease based on original articles and abstracts published in the last 30 years, with emphasis placed on the most recent placebo-controlled studies. Articles postulating the mechanisms of chelation also were included. The majority of the literature focused on three chelators in particular, ethylenediaminetetraacetic acid (EDTA), deferoxamine, and dexrazoxane (ICRF-187). Historically, much has been written on the beneficial effects of EDTA. However, there are few controlled studies, and the mechanism of action of EDTA is poorly understood. Although studies of deferoxamine are more recent, most of the research is limited to animals and ex vivo models. Recently, dexrazoxane was approved, but only for parenteral use for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer. Given these limitations, it is concluded that more controlled studies are required to determine the efficacy of chelation therapy in cardiovascular disease before it can be used broadly in the clinical setting.

References

Sep 15, 1975·JAMA : the Journal of the American Medical Association·A Soffer
Mar 1, 1992·Journal of Internal Medicine·B GuldagerS Ottesen
Jan 1, 1992·Cancer Chemotherapy and Pharmacology·T K YeungJ W Hopewell
Jan 1, 1991·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J CummingsJ F Smyth
Jan 1, 1991·Free Radical Research Communications·V M SamokyszynS D Aust
Jan 1, 1990·Free Radical Research Communications·B Halliwell
Apr 1, 1989·Journal of Cardiovascular Pharmacology·M P MaxwellD M Yellon
Jan 1, 1989·Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography·M W KellerS Kaul
Sep 1, 1988·Medical Hypotheses·E Olszewer, J P Carter
Jan 1, 1985·Journal of Free Radicals in Biology & Medicine·M SaitoS D Aust
Apr 1, 1984·The Biochemical Journal·B Halliwell, J M Gutteridge
Jun 1, 1983·Mutation Research·K HeindorffR Rieger
Dec 1, 1984·Drug Intelligence & Clinical Pharmacy·K L Rathmann, L K Golightly
Sep 1, 1994·Journal of Molecular and Cellular Cardiology·E E VoestA Bast
Mar 15, 1994·Annals of Internal Medicine·E E VoestJ J Marx
Jan 1, 1996·Acta Haematologica·C HershkoG Link
Jan 27, 1998·Current Problems in Cancer·W H FrishmanJ Dutcher
Jun 1, 1960·The American Journal of the Medical Sciences·N E CLARKER E MOSHER
Apr 1, 1963·The American Journal of Cardiology·J R KITCHELLL E MELTZER
Oct 7, 1964·Annals of the New York Academy of Sciences·H KEBERLE
Jan 1, 1989·IEEE Engineering in Medicine and Biology Magazine : the Quarterly Magazine of the Engineering in Medicine & Biology Society·M C van Gemert, A J Welch

❮ Previous
Next ❯

Citations

Feb 11, 2003·Journal of the American College of Cardiology·Todd J AndersonMerril L Knudtson
Jun 24, 2000·European Journal of Biochemistry·C LoskeG Münch
Jan 3, 2014·The Journal of Clinical Investigation·Yoshihiko IchikawaHossein Ardehali
Nov 3, 2005·BMC Cardiovascular Disorders·Dugald M R SeelyEdward J Mills
Jul 5, 2005·Expert Opinion on Investigational Drugs·H T Zhang, A L Harris
Mar 21, 2012·Journal of Cranio-maxillo-facial Surgery : Official Publication of the European Association for Cranio-Maxillo-Facial Surgery·G F DraenertW Wagner
Jun 13, 2001·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·S Y SaadA C Al-Rikabi
Dec 9, 2014·Journal of Pharmaceutical and Biomedical Analysis·Daniele BaniBarbara Valtancoli
Jun 28, 2016·Archives of Toxicology·Roberto Marques DamianiJenifer Saffi
Dec 19, 2001·The American Journal of Medicine·H QuanM L Knudtson
May 29, 2003·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Serguei LiachenkoYan Xu
Jun 10, 2017·Expert Review of Clinical Pharmacology·Sulaiman SultanArshad Jahangir
Jun 9, 2001·Antioxidants & Redox Signaling·V E KaganJ C Yalowich
May 23, 2007·Expert Opinion on Pharmacotherapy·Elly BarrySteven E Lipshultz
Jun 17, 2011·The Cochrane Database of Systematic Reviews·Elvira C van DalenLeontien Cm Kremer
May 20, 2016·British Journal of Clinical Pharmacology·Folefac AminkengUNKNOWN CPNDS Clinical Practice Recommendations Group
Mar 7, 2020·The Korean Journal of Physiology & Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology·Euncheol SonYoung-Hoon Kim
Jan 30, 2019·Proceedings of the National Academy of Sciences of the United States of America·Xuexian FangFudi Wang
Oct 7, 2020·Annual Review of Pharmacology and Toxicology·Konrad Teodor SawickiAlessandra Ghigo
Apr 13, 2021·Archives of Environmental & Occupational Health·Mustafa KaranfilÖzcan Özeke
May 29, 2021·The American Journal of the Medical Sciences·Daniel Glicklich, William H Frishman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.